Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Legend Biotech Corporation (NASDAQ: LEGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Legend Biotech files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together outline its financial performance, cell therapy pipeline, and key business developments.
In these filings, Legend Biotech presents unaudited interim condensed consolidated financial statements, including statements of profit or loss, financial position, changes in equity, and cash flows. Investors can review details on license revenue, collaboration revenue related to CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), research and development expenses, selling and distribution expenses, and collaboration funding arrangements. Management’s Discussion and Analysis (MD&A), often attached as exhibits to Form 6‑K, provides narrative context around revenue drivers, cost trends, and liquidity.
Filings also capture clinical and regulatory milestones. Recent 6‑Ks incorporate press releases on CARTITUDE‑1, CARTITUDE‑4, and CARTITUDE‑6 study updates, FDA and European Commission label changes for CARVYKTI, and early data from programs such as LUCAR‑G39D, LB2102, and LB1908. Additional 6‑Ks describe agreements with Janssen for component and product supply, preliminary sales figures for CARVYKTI, and participation in major scientific and investor conferences.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 6‑K and 20‑F filings, helping users quickly identify information on revenue composition, cell therapy pipeline status, collaboration structures, and risk disclosures. Real‑time ingestion of EDGAR updates ensures that new Legend Biotech filings, including any Form 6‑K related to financial results or material agreements, appear promptly.
Users can also monitor equity and compensation-related disclosures via Legend Biotech’s registration statements on Form S‑8, as referenced in its 6‑K reports, and review how these interact with share‑based compensation expenses reported in the financial statements. While Legend Biotech does not file Forms 3, 4, and 5 as a U.S. domestic issuer would, this page centralizes its available SEC reporting so investors can follow the company’s development as a global cell therapy business.
Legend Biotech Corp director Ji Darren Xiaohui reported his initial ownership on a Form 3. He directly holds 63,773 ordinary shares, including 34,662 restricted share units that vest in staged quarterly installments through future dates. He also holds an option immediately exercisable for 30,000 ordinary shares at an exercise price of 11.50, expiring on June 5, 2030. Each American Depositary Share represents two ordinary shares.
Legend Biotech Corp director Zhang Fangliang filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not list any specific share or option holdings and shows no recent insider transactions.
Legend Biotech Corp’s Chief Financial Officer, Carlos E. Santos, has filed an initial Form 3 insider ownership statement. The filing identifies him as an officer of the company with the title Chief Financial Officer and does not list any specific transactions in the provided excerpt.
Legend Biotech Corp director Sanders Corazon (Corsee) D. has reported her initial equity holdings in the company. She holds 59,115 ordinary shares directly, which include 25,674 restricted share units that convert into one ordinary share each upon settlement.
She also holds a share option for 12,000 ordinary shares at an exercise price of $11.50 per share, expiring on June 5, 2030, and all of these option shares are immediately exercisable. The restricted share units vest in multiple quarterly installments beginning March 20, 2026 and June 20, 2026, subject to continued service. Each American Depositary Share represents two ordinary shares.
Legend Biotech Corp Chief Executive Officer Huang Ying filed an initial ownership report showing direct holdings of 257,374 Ordinary Shares. This total includes 43,010 restricted share units, with 28,119 shares scheduled to vest on March 20, 2026 and 14,891 on June 20, 2026, subject to continued service.
Huang also reports multiple share options over Ordinary Shares at exercise prices from $1.5000 to $27.5000, expiring between July 21, 2029 and April 2, 2033. Footnotes state that some options are immediately exercisable, while others vest on April 3, 2026. Each American Depositary Share represents two Ordinary Shares.
Legend Biotech Corp director Wang Ye reported ownership of 16 Ordinary Shares, held directly. The filing notes that the company’s Ordinary Shares may be represented by American Depositary Shares (ADSs), with each ADS representing two Ordinary Shares of Legend Biotech.
Legend Biotech filed its annual report outlining strong growth of its multiple myeloma therapy CARVYKTI and ongoing risks. Net trade sales of CARVYKTI reached approximately $1.9 billion in the year ended December 31, 2025, yet the company still recorded a net loss of $296.8 million, reflecting heavy R&D, manufacturing build-out and commercial investments.
The report emphasizes dependence on CARVYKTI, competition from other BCMA-targeted and cell therapies, and complex manufacturing and supply chain requirements. It also highlights extensive legal and operational risks tied to operations in China, potential impact of the Holding Foreign Companies Accountable Act, foreign exchange volatility, and emerging U.S. drug-pricing pressures, particularly most-favored-nation style initiatives.
Legend Biotech had an accumulated deficit of $2.0 billion as of December 31, 2025, with 369,886,369 ordinary shares outstanding, and warns that continued losses and regulatory, pricing and geopolitical uncertainties could materially affect its business and the value of its ADSs.
Legend Biotech reported strong growth for the fourth quarter and full year 2025, driven by its multiple myeloma cell therapy CARVYKTI. CARVYKTI generated net trade sales of approximately $555 million in the fourth quarter and $1.9 billion for the full year, and the franchise achieved full‑year profitability.
Total revenue for the quarter rose to $306.3 million from $186.5 million a year earlier, as collaboration revenue from the Janssen agreement increased sharply. Operating loss narrowed to $19.7 million from $79.3 million, reflecting higher gross profit from CARVYKTI, though quarterly net results shifted to a $30.9 million loss mainly due to unrealized foreign exchange impacts.
For 2025, Legend Biotech posted a net loss of $296.8 million, but adjusted net loss improved to $33.1 million. Adjusted net income for the fourth quarter was $2.5 million. The company ended 2025 with cash, cash equivalents and time deposits of about $949 million and states this balance supports its financial runway beyond 2026, when it believes it will reach company‑wide operating profit.
Legend Biotech Corporation has appointed Gareth Kung to its Board of Directors, effective February 2, 2026. He will serve as a Class II director with a term running until the company’s 2028 annual general meeting of shareholders and will chair the Audit Committee, replacing Tomas Heyman.
Kung brings extensive financial and semiconductor industry experience, including senior finance roles at Wuhan Xinxin Semiconductor Manufacturing, Alpha Power Solutions, VXI Global Solutions, Semiconductor Manufacturing International Corporation and Hanwha SolarOne. He holds multiple accounting qualifications across Hong Kong, England & Wales, Singapore and the United States, and an MBA from the University of Western Ontario.
As compensation, Kung will receive a restricted share unit award with a grant-date value of $270,000 under Legend Biotech’s RSU Plan, vesting over three years, plus annual cash retainers of $75,000 for Board service and $25,000 for chairing the Audit Committee.
FMR LLC has filed an amended Schedule 13G reporting a significant ownership position in Legend Biotech Corp. As of 12/31/2025, FMR LLC beneficially owned 48,294,445.48 Ordinary Shares, representing 13.1% of Legend Biotech’s outstanding Ordinary Shares.
FMR LLC reports sole voting power over 48,202,106.24 Ordinary Shares and sole dispositive power over 48,294,445.48 Ordinary Shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 48,294,445.48 shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Legend Biotech.